Pragnesh Patel, MD
Interventional Cardiology · Jefferson City, TNNPI 1568529006
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,823 of the $13,921 with a category attached, or 84.9%. It is spread thinly across 40 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $3,980 and has fallen 81.7% since, to $727 in 2025.
Across 548 payments — averaging $25.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$3K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
- Novartis$2K
- Johnson & Johnson$1K
- AstraZeneca$1K
- Cardiovascular Systems Inc.$757
- plus $5K from 34 others
Across 167 payments — averaging $1824.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$240K
- Boehringer Ingelheim Pharma GmbH & Co.kg$45K
- Novartis$20K
What the payments were for
- Travel & lodging$1,83713%
- Food & beverage$11,82385%
- Education$2602%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 10 | $2,847 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 65 | $1,734 |
| Novartis | 110 | $1,619 |
| Johnson & Johnson | 76 | $1,220 |
| AstraZeneca | 62 | $1,010 |
| Cardiovascular Systems Inc. | 29 | $757 |
| Amgen | 24 | $667 |
| Bayer | 26 | $415 |
| Sanofi-aventis U.S. LLC | 23 | $385 |
| Boston Scientific | 12 | $379 |
| Angiodynamics, Inc. | 4 | $369 |
| Shockwave Medical, Inc | 16 | $319 |
| Boehringer Ingelheim | 15 | $293 |
| Abiomed | 2 | $274 |
| Abbott | 3 | $201 |
| E.r. Squibb & Sons, L.L.C. | 11 | $194 |
| Biotronik Inc. | 3 | $159 |
| Medtronic(2 entities) | 6 | $157 |
| Amarin Pharma, Inc. | 7 | $126 |
| Esperion Therapeutics, Inc. | 6 | $114 |
| Merck | 6 | $91 |
| Scpharmaceuticals Inc. | 5 | $84 |
| Pfizer | 4 | $70 |
| Janssen Scientific Affairs, LLC | 2 | $49 |
| Lundbeck LLC | 2 | $38 |
| Novo Nordisk | 2 | $36 |
| Cardinal Health 200 LLC | 2 | $34 |
| Lexicon Pharmaceuticals, Inc. | 1 | $30 |
| Cvrx, Inc. | 1 | $30 |
| Acist Medical Systems, Inc. | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 2 | $26 |
| GSK | 1 | $25 |
| Vivaquant Inc, Dba Rhythm Express | 2 | $24 |
| Irhythm Technologies, Inc. | 1 | $23 |
| Philips North America LLC | 1 | $22 |
| Lantheus Medical Imaging, Inc. | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Cordis US CORP. | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$2,390
- Auryon Laser System 100-120 Vac$358
- LifeVest$316
- Impella$274
- Repatha$247
- XARELTO$239
- Penumbra System$191
- Diamondback Peripheral$161
- Solia$131
- BioMonitor$131
- Rivacor$131
- Edora$131
- Acticor$131
- FARXIGA$125
- RESONATE$115
- JARDIANCE$103
- Watchman$100
How this compares
$13,921 in reported general payments places this provider in the 65th percentile of 207 interventional cardiology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 326 | $323,567 |
| XareltoRivaroxaban | 337 | $316,068 |
| EntrestoSacubitril/Valsartan | 242 | $285,572 |
| BrilintaTicagrelor | 211 | $127,580 |
| FarxigaDapagliflozin Propanediol | 101 | $94,177 |
| JardianceEmpagliflozin | 43 | $38,416 |
| Repatha SureclickEvolocumab | 45 | $35,071 |
| MultaqDronedarone Hcl | 39 | $30,324 |
| Ranolazine ErRanolazine | 116 | $13,785 |
| VascepaIcosapent Ethyl | 24 | $11,515 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $10,821 |
| Nitroglycerin PatchNitroglycerin | 227 | $7,948 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 99 | $3,914 |
| Prasugrel Hcl | 43 | $3,497 |
| Atorvastatin Calcium | 470 | $3,399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $70 | $323,567326 claims |
| Johnson & JohnsonXarelto | $1,220 | $316,068337 claims |
| NovartisEntresto | $1,619 | $285,572242 claims |
| AstraZenecaBrilinta, Farxiga | $1,010 | $221,758312 claims |
| Boehringer IngelheimJardiance | $293 | $38,41643 claims |
| Sanofi-aventis U.S. LLCMultaq | $385 | $30,32439 claims |
| GSKTrelegy Ellipta | $25 | $10,82111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 207 interventional cardiology providers in Tennessee.
Other interventional cardiology in Jefferson City
- Jimmy KerriganNashville$644K
- Kashish GoelNashville$558K
- Brian JeffersonNashville$547K
- Malcolm FosterKnoxville$413K
- Mehul PatelGermantown$382K
- Michael MorseNashville$353K
- Nadia SuttonNashville$344K
- Ayaz RahmanKnoxville$251K
- Samuel HorrNashville$246K
- Joseph WeinsteinMemphis$218K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.